Objectives: The role of uric acid as a prognostic factor in patients with acute ST elevation myocardial infarction is controversial. The purpose of this study was to demonstrate the relationship between serum uric acid level and mortality during admission period and 30-day period after admission.
A cute myocardial infarction is one of the most predominant causes of mortality worldwide. There are some markers indicating unfavorable prognosis in patients with acute myocardial infarction. Uric acid is one of the markers that has been evaluated in research. The role of uric acid as a risk factor for cardiovascular disease or a prognostic factor is controversial. Uric acid is produced by the enzymatic activity of xanthine oxidase and is the final product of purine metabo-lism [1] . Xanthine oxidase produces oxidants in this process that may have a role in cardiovascular disease. Some studies suggested that uric acid can cause intracellular stress and inflammation leading to endothelial injury and enhancement of vasoconstrictor effects [2] .
According to much research, uric acid could be a marker of adverse prognosis in patients with acute myocardial infarction but there are studies that showed no relation between serum uric acid level and mortality rate. On the other hand, these studies differ in type of perfusion and number size [2] [3] [4] [5] [6] [7] [8] . Therefore, we designed an observational cohort study aimed at evaluating the relation between serum uric acid level and short-term mortality in patients with acute ST elevation myocardial infarction (STEMI).
Methods
The patients included in the study were selected consecutively among those admitted with acute STEMI on the basis of the following inclusion criteria: (1) resting chest pain lasting more than 30 min; (2) typical ischemic ST elevation in electrocardiogram (ECG) leads; and (3) rise of serum cardiac enzymes concentration (CK-MB and Troponins). We excluded patients who: (1) did not receive thrombolytic therapy during the first six hours after the onset of chest pain; (2) were in cardiogenic shock (3) had previous pacemaker implantation; (4) had a recent myocardial infarction (<3 months); (5) had severe valvular disease; (6) had impaired renal function (serum creatinine level >1.5 mg/dl); (7) had known cases of hypothyroidism, malignancy, gout or other inflammatory diseases and were using corticosteroid or cytotoxic drugs.
All patients underwent a standard 12-lead ECG and echocardiographic examination. ECGs were recorded at a speed of 25 mm/s and a scale of 10 mm/mV.
Patients were imaged in the left lateral decubitus position in the parasternal and apical views using a commercially available system (Vingmed Seven, General Electric-Vingmed, Milwaukee, WI, USA) during the first day of admission. Left ventricular ejection fraction (LVEF) was calculated from the conventional apical two-and four-chamber images, using the biplane Simpson's technique. Blood samples were obtained immediately after admission. Uric acid and other biochemical parameters were measured. We used Parsazmun photometric kits to measure uric acid. Serum creatinine and uric acid concentrations were expressed as milligrams per deciliter (mg/dl). Serum creatine kinase and creatine kinase-MB were measured and expressed as international units per liter (IU/L) and micrograms per liter (lg/L). Body weight and height were measured during admission and Body Mass Index (BMI) was calculated.
Hypertension was defined as taking antihypertensive drugs or baseline blood pressure equals to 140/90 mmHg or more. Diabetes Mellitus (DM) was defined as taking hypoglycemic agents or fasting plasma glucose level at or above 126 mg/dl, a two-hour value in an oral glucose tolerance test at or above 200 mg/dl, or a random plasma glucose concentration P200 mg/dl in the presence of symptoms. Hyperlipidemia was defined as a total cholesterol level P220 mg/dl or a triglyceride level P150 mg/dl. Active smoking was defined as risk factor.
Normal levels of uric acid were defined 2.5-5.6 mg/dl in women and 3.1-7 mg/dl in men according to our reference laboratory.
The patients underwent selective coronary angiography and revascularization according to current guidelines [9] .
We divided the patients into four groups according to their serum uric acid level and gender. Group A 1 consisted of male patients with serum uric acid level of 7 mg/dl or less and group B 1 consisted of male patients with serum uric acid level more than 7 mg/dl. Group A 2 consisted of female patients with serum uric acid level of 5.6 mg/dl or less and group B 2 consisted of female patients with serum uric acid level more than 5.6 mg/dl. ASA, beta blockers, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers and statins were prescribed for all of the patients during admission and after discharge. We followed the patients for 30 days after admission.
The primary aims of the study were comparing mortality from any cause during the 30-day period after STEMI and the in-hospital mortality rate between groups.
The study protocol was approved by ethics committee of Jundishapur University of Medical Sciences. All patients provided written informed consent.
Continuous data were expressed as mean ± standard deviation values.
Fisher's exact test and Chi-square test and student t-test were used to compare groups. For correction of potential confounding factors on inhospital mortality and short-term mortality, we used backward elimination multivariate logistic. A P-value less than 0.05 was considered to be statistically significant.
Results
The study population consisted of 184 patients [129 men (70.1%) and 55 women (29.9%)].The mean age was 58 ± 11.7 years (range: 26-80 year) and the mean body mass index (BMI) was 26.54 ± 1.31 (23-32.1).
Sixty-eight (37%) patients had hypertension. History of DM, hyperlipidemia and smoking were present in fifty-four (29.3%), sixty-one (33.2%) and eighty-give (46.2%) cases, consecutively.
Fifty-five patients (29.9%) had a history of coronary artery disease. Eight patients (4.3%) had history of coronary artery bypass graft (CABG) surgery and seventeen cases (9.2%) had history of percutaneous coronary intervention (PCI). Ninety-four patients (51.1%) had anterior myocardial infarction and ninety patients (48.9%) had inferior myocardial infarction. The time from chest pain onset was 2.91 ± 0.48 h (range: 1.5-4 h).One hundred and fifty-four patients (83.7%) were in Killip's class I and the remainder were in Killip's class II. The mean of serum creatinine level was 1.06 ± 0.24 mg/dl (range: 0.5-1.5 mg/dl) and the mean of serum uric acid level was 5.74 ± 1.91 mg/dl (range: 2-12 mg/dl).
Mean LVEF was 41.2 ± 9.3% (range: 10-60%). The duration of hospitalization was 7.3 ± 3.5 day (range: 2-30 day).
Patients' baseline characteristics in group A 1 versus group B 2 and group A 2 versus group B 2 are presented in Tables 1 and 2 .
There was no significant difference between the patient's baseline characteristics in group A 1 versus group B 1 except age and serum creatinine level. We did not find any significant difference between patient's baseline characteristics in group A 2 versus group B 2 .
Cardiac events were the cause of mortality in all our patients.
The in-hospital mortality rate in group B 1 was higher than group A 1 In female patients (group A 2 versus group B 2 ), we did not find any significant relation between serum uric acid level and in-hospital and shortterm mortality.
After adjusting for age, hypertension, DM, dyslipidemia, smoking, BMI, ejection fraction and serum creatinine level, multivariate logistic regression analysis of data showed a significant difference between group A 1 and group B 1 and uric acid was confirmed as an independent predictor for in-hospital mortality [odds ratio: 15.23 (95% confidence interval: 1.39-117.3)] and short term mortal- Table 1 . Baseline characteristics of patients in group A 1 (UA 6 7 mg/dl) and patients in group B 1 (UA > 7 mg/dl). Tables 3 and 4 . Ninety-one patients underwent selective coronary angiography that showed multi-vessel disease in fifty-four patients (59.3%) and significant LAD lesion in seventy-six patients (83.5%). Seventeen of fifty-two patients in group A 1 who underwent coronary angiography had multi-vessel disease while eight of the sixteen group B 1 patients had multi-vessel disease. Ten of the twenty-seven patients in group A 2 had multi-vessel disease while nine of the fifteen group B 2 patients who underwent coronary angiography had multi-vessel disease. There was no statistically significant difference between groups.
Thirty-nine patients in group A 1 and twelve patients in group B 1 had significant LAD lesions. Fifteen patients in group A 2 had significant LAD lesions while ten of the group B 2 patients who underwent coronary angiography had significant LAD lesions. There was no significant difference in LAD lesion prevalence between groups.
During follow up, four patients of group A 1 and two patients of group B 1 underwent CABG and nine patients of group A 1 and six patients of group B 1 underwent PCI. One patient in group A 2 and one patient in group B 2 underwent CABG. Three patient of group A 2 and three patients of group B 2 underwent PCI. Therefore, there was no significant difference between revascularization rates between groups.
No device was implanted during follow up.
Discussion
In the present study, we found a strong relation between serum uric acid levels at the time of admission and in-hospital and short-term mortality in male patients with STEMI. The all-cause mortality rate of male patients with serum uric acid concentrations of more than 7 mg/dl or more was 3.76 times higher than those with uric acid concentrations of 7 mg/dl or more during the first month after admission.
The role of uric acid as a risk factor for myocardial infarction is controversial. There are a lot of studies suggesting that hyperuricemia is a risk factor for cardiovascular disease [10, 11] . The Framingham Heart study demonstrated that uric acid was not a risk factor for cardiovascular events [11] , and therefore most medical societies have not considered serum uric acid level as a cardiovascular risk factor [11] .
Whereas Homayounfar et al. [4] concluded that uric acid was not an independent prognostic marker for in-hospital mortality after acute myocardial infarction, there are many studies that have showed uric acid could be a marker of adverse prognosis in patients with acute myocardial infarction [3, [5] [6] [7] [8] . Recently, Wasserman et al. documented that uric acid was an independent predictor of in-hospital mortality in medical patients [1] .
To clarify how uric acid plays a role as a prognostic factor in STEMI, production of uric acid is elevated in association with increased xanthine oxidase activity. During uric acid production, oxygen free radicals are generated and therefore, uric acid may be a simple and useful clinical indicator of excess oxidative stress [6, 12] . The generation of oxygen free radicals is one of probable mechanisms involved in the no-reflow phenomenon during reperfusion therapy. On the other hand, hyperuricemia is associated with decreased production of nitric oxide and endothelial dysfunction and myocardial microvascular disease and local inflammation [2, 6] .
Hyperuricemia may also be related to impaired uric acid excretion caused by low cardiac output and tissue hypoxia. In some studies, serum uric acid level correlated with severity of the Killip classification [5, 8] . In our patients, the creatinine level in group B patients was higher than group A but the Killip's class and LVEF and other clinical characteristics of both groups were not different. So, the difference in cardiac output could not explain this in our patients.
We did not find any relation between hyperuricemia and short-term mortality in female patients with STEMI. The most possible explanation could be the low number of our patients.
In conclusion, although there are other biomarkers correlating with increased mortality risk in patients with STEMI, our study supported that serum uric acid could be another potential important biomarker of short-term mortality.
Some limitations of our study also need to be acknowledged. The major limitation of the present study may be represented by the small number of patients. Also, we did not compare the prevalence of using drugs like thiazide diuretics or other usual drugs than can change serum uric acid level among our groups. Another limitation is that most of our patients were male. A large study, especially with more female patients, could be more informative. Another limitation of the study is that we did not follow the exact adherence rate of our patients to their prescribed drugs.
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Conclusion
Our data suggest that serum uric acid level has a prognostic role in in-hospital and 30-day mortality of male STEMI patients. This can be a useful biomarker for predicting short-term mortality in this group of patients.
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